This post was originally published on this site
“During the fiscal third quarter, our team delivered strong profitability with 32% EBITDA and solid cash flow against persisting demand weakness in electronics and biopharma end markets. The team remains focused on the execution of our Ascend strategy to achieve top tier growth with leading margins and returns, as evidenced by the recently announced acquisition of ARAG and the steadfast deployment of the NBS Next growth framework,” said CEO Sundaram Nagarajan.
The company narrowed its previously issued full 2023-year revenue growth guidance to 0% to 2% over record fiscal 2022. Adjusted EPS for the full year is expected to be in the range of $8.90 to $9.05.
